Molecular structure of Palmitoylethanolamide, CAS Number: 544-31-0
Palmitoylethanolamide (CAS 544-31-0)
Alternate Names:
Palmitoylethanolamide is also known as PEA.
Application:
Palmitoylethanolamide is an endogenous cannabinoid agonist, FAAH inhibitor, and PPARα agonist.
CAS Number:
544-31-0
Purity:
>99%
Molecular Weight:
299.50
Molecular Formula:
C18H37NO2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Palmitoylethanolamide is an endogenous cannabinoid. Palmitoylethanolamide is a weak ligand of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors. It has been found that Palmitoylethanolamide can inhibit fatty acid amide hydrolase. Palmitoylethanolamide exhibits anti-nociceptive, anti-inflammatory, anti-convulsant and immunosuppresant activity. Palmitoylethanolamide acts by binding to an unidentified cannabinoid receptor that is similar to CB2.
Palmitoylethanolamide (CAS 544-31-0) References
- Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. | Lambert, DM., et al. 1999. Biochim Biophys Acta. 1440: 266-74. PMID: 10521710
- Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. | Jonsson, KO., et al. 2001. Br J Pharmacol. 133: 1263-75. PMID: 11498512
- Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. | Capasso, R., et al. 2001. Br J Pharmacol. 134: 945-50. PMID: 11682441
- Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. | De Petrocellis, L., et al. 2002. Fundam Clin Pharmacol. 16: 297-302. PMID: 12570018
- The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. | Lo Verme, J., et al. 2005. Mol Pharmacol. 67: 15-9. PMID: 15465922
- Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. | Murillo-Rodriguez, E., et al. 2006. Life Sci. 79: 30-7. PMID: 16434061
- Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. | D'Agostino, G., et al. 2012. Neuropsychopharmacology. 37: 1784-92. PMID: 22414817
- Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. | Esposito, E., et al. 2012. PLoS One. 7: e41880. PMID: 22912680
- Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. | Crupi, R., et al. 2013. CNS Neurol Disord Drug Targets. 12: 989-1001. PMID: 23844686
- Potential Mechanisms Involved in Palmitoylethanolamide-Induced Vasodepressor Effects in Rats. | Marichal-Cancino, BA., et al. 2020. J Vasc Res. 57: 152-163. PMID: 32248195
- Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. | Facci, L., et al. 1995. Proc Natl Acad Sci U S A. 92: 3376-80. PMID: 7724569
- The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. | Skaper, SD., et al. 1996. Proc Natl Acad Sci U S A. 93: 3984-9. PMID: 8633002
- Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. | Cadas, H., et al. 1996. J Neurosci. 16: 3934-42. PMID: 8656287
- N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. | Mazzari, S., et al. 1996. Eur J Pharmacol. 300: 227-36. PMID: 8739213
- Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. | Bisogno, T., et al. 1997. J Biol Chem. 272: 3315-23. PMID: 9013571
Inhibitor of:
FAAH, FLJ37512, Lipocalin-15, Lipocalin-9, LRFN5, OR4D11, RD3, Retinoschisin, V1RB4, Vmn2r95, and ZDHHC25.Activator of:
17β-HSD11, ABHD10, ABHD12, ABHD15, ABHD9, ACSBG2, ACSL6, Angptl2, APOP1, ASAHL, ATP10D, Bcl-rambo, C14orf43, C15orf24, C20orf3, C5orf30, CNR1, CNR2, DBC-2, DBT, DHRS4L2, E-FABP, ENHO, ERAB, FAAH2, FAM57A, Fbxo12, FNDC3A, FUNDC2, GPR10, GPR55, GS2-like, IFN-α7, Intectin, KRTAP5-4, LOC55908, MBOAT1, MBOAT4, MerTK, mMGL, MrgB4, MrgB5, MrgB8, MrgH, MTP18, NAPE-PLD, Nir3, PAP-2c, PDRG, PECI, PIG-N, PPAR alpha, RBQ-1, RECS1, RED2, Reg IIIδ, Retinal RX2, SAA3, SLC25A36, TREK-1, TRIM16, TUSC5, VSIG6, and XYLB.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Palmitoylethanolamide, 10 mg | sc-202754 | 10 mg | $78.00 | |||
Palmitoylethanolamide, 50 mg | sc-202754A | 50 mg | $238.00 | |||
Palmitoylethanolamide, 500 mg | sc-202754B | 500 mg | $2050.00 | |||
Palmitoylethanolamide, 1 g | sc-202754C | 1 g | $3274.00 | |||
Palmitoylethanolamide, 10 g | sc-202754D | 10 g | $16330.00 |